HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Buprenorphine Hydrochloride; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application ANDA219647. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TRAMADOL HYDROCHLORIDE.

Supporting Context

Therapeutic area
Pain Management · Opioid
Sub-indication
Pain

Related signal: FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

Source

View source document

Related Signal

Open signal — FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.